Splenomegaly predicts survival of patients receiving immune checkpoint inhibitors for advanced primary liver cancer

Immune checkpoint inhibitors (ICIs) play an increasingly important role in the treatment of primary liver cancer (PLC). Some patients with PLC experience symptoms of splenomegaly. This may affect the efficacy of ICIs due to an imbalance of the immune microenvironment. A retrospective cohort study at Southern Medical University (Guangzhou, China) found that in patients receiving ICIs for advanced primary liver cancer, splenomegaly was associated with worse overall survival and worse progression-free survival.